Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

(2009) B Komoroski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

(2009) B Komoroski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment

(2009) J. P.H. Wilding et al.   DIABETES CARE

Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

(2008) S. Han et al.   DIABETES

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

(2008) J. F. List et al.   DIABETES CARE

Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

(2008) Wei Meng et al.   JOURNAL OF MEDICINAL CHEMISTRY

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Intensive Glucose Lowering in Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes

(2008) William Duckworth et al.   NEW ENGLAND JOURNAL OF MEDICINE